Thermo Fisher and Evosep Partner to Offer Next-Generation Proteomics Platform
News related to:Evosep · 2 min read
SINGAPORE, Sept. 28, 2026 /CourierPR/ -- Thermo Fisher Scientific and Evosep have entered into a reseller agreement, allowing Thermo Fisher to offer the Evosep Eno separation platform as part of its mass spectrometry solutions portfolio. This collaboration aims to provide researchers with streamlined access to next-generation LC-MS based proteomics workflows.
Evosep, a global leader in standardized proteomics solutions, has developed the Evosep Eno platform to address the growing need for standardized proteomics in research, drug discovery, and clinical applications. The platform is designed to deliver exceptional robustness, ease of use, and throughput, enabling laboratories to generate high-quality data at scale while minimizing operational complexity.
Through this agreement, customers will be able to purchase the Evosep Eno directly through Thermo Fisher Scientific, creating a seamless customer experience and enabling tighter integration between Evosep’s workflow solutions and Thermo Fisher’s mass spectrometry ecosystem. Key benefits for customers include standardized and reproducible proteomics, high throughput without compromise, streamlined workflow integration, and scalability for emerging applications.
The Evosep Eno platform supports a broad range of applications, including large population studies, biomarker discovery, drug development, and future clinical proteomics initiatives.
Thermo Fisher Scientific will showcase the Evosep Eno at Booth #220 during the HUPO 2026 conference, which is scheduled to take place in [Location]. Attendees will have the opportunity to learn more about the platform and its potential impact on proteomics research.
The agreement combines Thermo Fisher Scientific’s global commercial reach and industry-leading mass spectrometry instruments with Evosep’s innovative separation technology, enabling laboratories around the world to implement robust, scalable, and highly reproducible proteomics workflows. By delivering exceptional robustness, ease of use, and throughput, Evosep Eno helps laboratories generate high-quality data at scale while minimizing operational complexity.
Evosep aims to improve quality of life and patient care by radically innovating protein-based clinical diagnostics, initially through collaborations with world-leading scientists. The company’s focus is on developing new technologies and solutions to make sample separation 100 times more robust and 10 times faster than today’s alternatives.
The reseller agreement represents an important step in expanding access to scalable proteomics technologies and reflects both companies’ commitment to advancing life science research through innovation, standardization, and operational excellence.